Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CXCL12 inhibitor

DRUG CLASS:

CXCL12 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

tipifarnib (36)

tipifarnib (36)

›

HRAS mutation	Squamous Cell Carcinoma of Head and Neck	HRAS mutation	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B
No biomarker	Glioblastoma	No biomarker	Glioblastoma	NOX-A12 Sensitive: B - Late Trials NOX-A12 Sensitive : B	NOX-A12 Sensitive: B - Late Trials NOX-A12 Sensitive : B
HRAS mutation	Urothelial Cancer	HRAS mutation	Urothelial Cancer	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	NOX-A12 Sensitive: C3 – Early Trials NOX-A12 Sensitive : C3	NOX-A12 Sensitive: C3 – Early Trials NOX-A12 Sensitive : C3
HRAS G13R	Urothelial Cancer	HRAS G13R	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS Q61R	Urothelial Cancer	HRAS Q61R	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS G12S	Urothelial Cancer	HRAS G12S	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS G12C	Urothelial Cancer	HRAS G12C	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS H27_28fs*	Urothelial Cancer	HRAS H27_28fs*	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
CXCL12 overexpression	T Cell Non-Hodgkin Lymphoma	CXCL12 overexpression	T Cell Non-Hodgkin Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
KIR3DL2 Q386E	T Cell Non-Hodgkin Lymphoma	KIR3DL2 Q386E	T Cell Non-Hodgkin Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
KIR3DL2 C336R	T Cell Non-Hodgkin Lymphoma	KIR3DL2 C336R	T Cell Non-Hodgkin Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3